Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
WEBINAR: Bioanalytical challenges and strategies of T-cell engager therapeutics 9 days 4 hours 13 mins 50 secs REGISTER NOW

The technology behind Bio-Rad’s custom recombinant antibodies

25 Oct 2017
Antibodies | ADCs

Take a look inside Bio-Rad’s custom recombinant antibody facility. Learn from our antibody experts how your requirements for specialized anti-biotherapeutic antibodies can become a reality through the use of HuCAL technology.


For more information on Bio-Rad, please click here.

Top content

  • New AI tool predicts multiple sclerosis drug response
  • Small molecule method development strategies with Chad Christianson
  • Webinar Q&A follow-up: A masterclass in advanced analytical assays for bioanalysis of oligonucleotides

Related tags

antibody Bio-rad biotherapeutics technology
Previous article Next article

Related articles

5 APR 2016 ANTIBODIES | ADCS
Sensitive assays enable detection of serum IgG antibodies against Clostridium difficile toxin A and toxin B in healthy subjects and patients with Clostridium difficile infection
4 OCT 2012 DATA PROCESSING AND INTERPRETATION
Immunological screening and characterization of highly specific monoclonal antibodies against 20 kDa hGH
3 OCT 2013 AUTOMATION
A generic template for automated bioanalytical ligand-binding assays using modular robotic scripts in support of discovery biotherapeutic programs
2 SEP 2014 CLINICAL
New optical device may improve skin cancer diagnostics
29 APR 2019 EXPERT OPINION
Recent developments in flow cytometry analyzers and cell sorters
4 MAR 2015 GENERAL INTEREST
Paper test strip device developed for rapid Ebola diagnosis
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 Bioanalysis Zone